A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the
Efficacy and Safety of Abrocitinib (PF-04965842) in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects. A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of Abrocitinib (PF 04965842) in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects.